Aurora CannabisACB 59 Return-on-Tangible-Equity is -61.41% as of Mar. 2026. GuruFocus rates ACB with a GF Score™ of 59/100 and a GF Value™ of $4.22 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 897 Drug Manufacturers companies, Aurora Cannabis ranks worse than 88.18% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Aurora Cannabis's annualized net income for the quarter that ended in Mar. 2026 was $-207.3 Mil. Aurora Cannabis's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $337.5 Mil. Therefore, Aurora Cannabis's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -61.41%.
The historical rank and industry rank for Aurora Cannabis's Return-on-Tangible-Equity or its related term are showing as below:
ACB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -493.83 Med: -41.05 Max: 19.6
Current: -29.06
During the past 13 years, Aurora Cannabis's highest Return-on-Tangible-Equity was 19.60%. The lowest was -493.83%. And the median was -41.05%.
ACB's Return-on-Tangible-Equity is ranked worse than 88.18% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs ACB: -29.06
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Aurora Cannabis Return-on-Tangible-Equity Related Terms
Aurora Cannabis Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Aurora Cannabis's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACB vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aurora Cannabis's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aurora Cannabis Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aurora Cannabis's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Aurora Cannabis's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -61.41% mean?
Aurora Cannabis (ACB) has a Return-on-Tangible-Equity of -61.41% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aurora Cannabis and its competitors. According to the industry distribution chart, Aurora Cannabis ranks #791 out of 897 companies in the Drug Manufacturers industry, placing it in the top 88.2%.
Is Aurora Cannabis' Return-on-Tangible-Equity too high?
Aurora Cannabis' current Return-on-Tangible-Equity is -61.41%. Based on the distribution chart, Aurora Cannabis ranks #791 out of 897 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Aurora Cannabis has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aurora Cannabis' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aurora Cannabis ranks #791 out of 897 companies for Return-on-Tangible-Equity. This places Aurora Cannabis in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Aurora Cannabis and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aurora Cannabis's current Return-on-Tangible-Equity is -61.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aurora Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Aurora Cannabis (ACB) is currently considered Possible Value Trap. The stock's GF Value™ is $4.22, compared to a current price of $2.79 — trading 33.9% below its estimated fair value. The current Return-on-Tangible-Equity is -61.41%. Aurora Cannabis' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Aurora Cannabis (ACB), the current Return-on-Tangible-Equity is -61.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aurora Cannabis (ACB) Overvalued in 2026?
Based on GuruFocus' analysis, Aurora Cannabis stock appears to be undervalued.
The current stock price of $2.79 is trading 33.9% below its estimated GF Value™ of $4.22.
GuruFocus considers Aurora Cannabis to be Possible Value Trap.
Key valuation signals for ACB:
Return-on-Tangible-Equity: -61.41%
GF Value™: $4.22 vs. price of $2.79 (33.9% below fair value)
No single metric tells the full story. See the ACB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
59GF Score
Get the complete analysis for ACB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACB has been successfully added to your 
